Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Northera Confirmatory Trial Could Recruit Patients From Expanded Access Program

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA was unreceptive to Chelsea’s proposal to change endpoint in on-going 306B study to provide confirmatory efficacy data for droxidopa in neurogenic orthostatic hypotension.

Advertisement

Related Content

Northera Ongoing Trial May Satisfy FDA Request For More Efficacy Data, Chelsea Says
Not The Next Avastin? Plan For New ProAmatine Studies Would Negate Shire’s Withdrawal Hearing Request

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS074451

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel